- The BMJ iPad app brings you the best of print and online, including live links to the latest news, blogs, video, and podcasts. Get the BMJ iPad app.
- Find out how study types differ in our How to read a paper section.
- Gastroenterology updates: Access the latest gastroenterology resources from across BMJ Group, including articles, learning modules, podcasts, and blogs.
-
OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper. - Keep up to date with diabetes: Access the latest diabetes resources from across BMJ Group, including articles, learning modules, podcasts, and blogs.
- Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group.
- Hot topics: We regularly publish more than one article on the same subject simultaneously. Find out more on our article clusters page.
- Dementia: Access the latest dementia resources from across BMJ Group, including articles, learning modules, podcasts, and blogs.
- Neurology updates: Access the latest neurology resources from BMJ Group, including articles, learning modules, podcasts, and blogs.
- Infectious diseases: Access the latest infectious disease resources from across BMJ Group, including articles, learning modules, podcasts, and blogs.
- Updates from bmj.com: Get RSS feeds of latest articles published at bmj.com/rss
Tamiflu
- BMJ open data campaign
- News: Cochrane group rejects Roche’s offer of “advisory board” to discuss analysis of oseltamivir data
- News: MPs are to investigate need for drug companies to share clinical trial data
- Editorial: The new BMJ policy on sharing data from drug and device trials
- News: Roche should be sued to release data on oseltamivir, says Cochrane leader
- Podcast: Fishy data
- Editorial: Clinical trial data for all drugs in current use
- Feature: Tamiflu: the battle for secret drug data
- Observations: Open letter to Roche about oseltamivir trial data
- News: Questions remain over safety and effectiveness of oseltamivir
- Feature: Search for evidence goes on
- Analysis: Rethinking credible evidence synthesis
- Feature: WHO and the pandemic flu “conspiracies”
- Editorial: Conflicts of interest and pandemic flu
- Editor’s Choice: We want raw data, now
- Editorial: Why don’t we have all the evidence on oseltamivir?
- Research: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
- Feature: Complications: tracking down the data on oseltamivir
- Analysis: What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?
- Analysis: Neuraminidase inhibitors—the story behind the Cochrane review
- Letter: Point-by-point response from Roche to BMJ questions
- Letter: Roche replies to the authors of the Cochrane Review on oseltamivir
- Feature: Flu’s unexpected bonus
- Letter: Roche responds
- Research: Neuraminidase inhibitors for treatment and prophylaxis of influenza in children
